Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhou Deng

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
British Journal of Pharmacology|August 1, 2019
A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk<sup>C481S</sup> mutation in B-cell malignanciesFu Gui, Jie Jiang, Zhixiang He, et al.
Cancer Research|October 21, 2016
Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase InhibitorsJie Jiang, Fu Gui, Zhixiang He, et al.
EMBO Molecular Medicine|November 30, 2021
A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLCYue Lu, Zhenzhen Fan, Su-Jie Zhu, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
British Journal of Pharmacology|August 1, 2019
A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk<sup>C481S</sup> mutation in B-cell malignanciesFu Gui, Jie Jiang, Zhixiang He, et al.
Cancer Research|October 21, 2016
Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase InhibitorsJie Jiang, Fu Gui, Zhixiang He, et al.
EMBO Molecular Medicine|November 30, 2021
A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLCYue Lu, Zhenzhen Fan, Su-Jie Zhu, et al.
Pageof 8